You searched for "MIGS"
Evolving towards an interventional glaucoma mindset
Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...
Morning glory syndrome associated with PHPV
This is a retrospective review of the medical records of 85 eyes / 74 patients diagnosed as morning glory syndrome (MGS) in the clinic between November 2009 and November 2012. Twenty two eyes of 19 patients diagnosed as having MGS...The National Student Ophthalmology Conference 2024
This will be our third annual conference, hosted virtually with the aim to inform and inspire current medical students with interests in ophthalmology. It is a collaborative effort of student representatives from medical schools across the country. - 8 guest...
One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management
The authors report a retrospective, non-randomised interventional case series of 39 patients who underwent a standalone XEN45 implantation. All 39 patients (female: male=1.2: 1) completed 12-month follow-up. Mean age was 70.1 years (range 32–92). Primary outcome measures were the intraocular...
MicroRNA inhibits corneal neovascularisation
MicroRNAs (miR) are small non-coding RNA that target mRNA for destruction. MiR target about 30% of the protein coding genes and fine tune their expression. MiR have been shown to be involved in several cellular processes including cell cycle, tissue...Sight Sciences at ESCRS
The Sight Sciences team recently returned from an incredibly busy and successful ESCRS congress in Copenhagen. The team were in town to support the MIGS masterclass programme and were pleased to spend time with customers, colleagues and contacts from across...Glaukos marks major milestone as global iStent sales reach 3 million
Glaukos is delighted to announce a major milestone revealing that 3 million iStents have been sold globally since the product first received approval from the FDA in 2012. Today iStent is the global market leader in the MIGs category with...UKEGS (UK and Éire Glaucoma Society) Conference 2024
Pretty soon it’s going to be the 9th of October, and a quick Wikipedia search will tell you of how this day in history has seen the founding of the Kingdom of Valencia, the initial whispers of the Prague Astronomical...Sharing best practice and landmark evidence in glaucoma care
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...Preview: UKEGS 2024
Pretty soon it’s going to be the 9th of October, and a quick Wikipedia search will tell you of how this day in history has seen the founding of the Kingdom of Valencia, the initial whispers of the Prague Astronomical...Cutting-edge practice in glaucoma care: what, how and why?
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...
